Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Cambridge Nutritional Sciences PLC (CNSL)

London
Currency in GBP
Disclaimer
3.85
-0.15(-3.75%)
Closed

CNSL Comments

I think that tweet over the weekend was purposely tweeted to drop the SP so the directors could buy more prior to the big announcement.
Do you have any news on omega?
Omega Diagnostics confirms deal with UK to manufacture Covid lateral flow tests.Everything falling into place here.
Getting really exciting now, endorsement as a key UK government manufacturer in the FT. Government orders in the pipeline. Huge upside.
This SP will easily reach £2 this year. Strong fundamentals, orders are around the corner. MHRA Approval imminent. US, India and China orders coming soon.
In four months, this company will be manufacturing 2m+ C-19 tests / week with an avg profit of £1 / test. It will generate more profit more than its current mcap. It has a huge diversification of high quality tests in partnership with Mologic and a part of the UK-RTC set up by the uk gov. The company also has food intolerance and CD4 divisions as well as developing LFT for Cryptococcus and TB -LAM, underpinning the company's value post covid. Price target of 250p (£475m mcap)
Or in four months this company could still be sat waiting for orders, capacity is one thing... but IP and orders is what counts. On the covid front they have neither.
Biolidics Enters Distribution Agreement With Mediproud Co for COVID19 test Kits
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.